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Background: Cervical cancer is the most common cancer among women of reproductive age in Thailand.
However, information on the prevalence and correlates of anogenital HPV infection in Thailand is sparse.
Methods: HPV genotype information, reproductive factors, sexual behavior, other STI and clinical information, and
cervical cytology and histology were assessed at enrollment among one thousand two hundred and fifty-six (n = 1,256)
HIV negative women aged 20–37 from Thailand enrolled in a prospective study of the natural history of HPV. The
type-specific prevalence of HPV was estimated using cervical swab specimens from healthy women and women
with a diagnosis of CIN 2/3 at baseline. Prevalence ratios (95% CI) were estimated using Poisson regression to
quantify the association of demographic, behavioral, and clinical correlates with prevalent HPV infection.
Results: Overall, 307 (24.6%) and 175 (14.0%) of women were positive for any HPV type and any HR-HPV type,
respectively; the most common types were 72, 52, 62, and 16. Among women diagnosed with CIN 2/3 at enrollment
(n = 11), the most prevalent HPV types were 52 and 16. In multivariate analysis, HPV prevalence at enrollment was
higher among women with: long-term combined oral contraceptive use, a higher number of lifetime sexual partners, a
prior Chlamydia infection, and a current diagnosis of Bacterial Vaginosis.
Conclusion: The study findings provide important information that can be used in the evaluation of primary and
secondary interventions designed to reduce the burden of cervical cancer in Thailand.
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Cervical cancer affects nearly half a million women
worldwide, making it the third most common cancer.
Between the years 1983 and 2002, Thailand had a re-
ported average annual cervical cancer incidence rate of
65.2 cases per 100,000 over the 20 year period making it
the most common cancer among women between 30–
74 years of age with a 2.6% per year increase in inci-
dence [1]. Infection with anogenital types of the human
papillomavirus (HPV) is the established cause of cer-
vical cancer [2,3]. HPV types 16 and 18 account for
nearly 70% of the total cervical cancer cases detected* Correspondence: morgan.marks@merck.com
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unless otherwise stated.worldwide with HPV 16 alone accounting for approxi-
mately 50% [4].
In a prior population-based study in two districts in
northern and southern Thailand, HPV types other than
type 16 were as or more prevalent in women both with
and without cervical disease [5]. However, this prior
work provided only a limited view of the total HPV bur-
den as it included women from only 2 regions in
Thailand. Given the large burden of cervical cancer in
Thailand, it is important to further understand the HPV
type-specific distribution in cervical infections in other
regions and populations. This information may help
direct appropriate strategies for current and future
interventions.
The current study assessed the prevalence and risk
factors for anogenital HPV infection and CIN 2/3 inhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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clinics in 7 sites throughout the country.
Methods
Study population and enrollment
Women 20–37 years old attending family planning
clinics in the northern (Chiang Mai), northeastern (Khon
Kaen), central (Bangkok) and southern (Songkla/HatYai)
regions in Thailand between 2002–2003 were recruited
into a prospective study investigating the natural history
of HPV and CIN 2/3. These women were previously en-
rolled in a two-year study addressing the effects of hor-
monal contraceptive use on HIV acquisition (HC-HIV).
Selection criteria are described in detail elsewhere [6].
Briefly, inclusion criteria for enrollment in the HC-HIV
study were: 1) HIV negative; 2) not pregnant; 3) intact
uterus; 4) used some form of contraception in the
3 months prior to enrollment; and 5) willing to adhere
to the self-selected contraceptive method for at least
1 year of follow-up. Among women who participated in
the HC-HIV study, 79% were reconsented for inclusion
in the current study (n = 1256). The study protocols
were reviewed and approved by the committees on hu-
man subject research at Johns Hopkins Bloomberg
School of Public Health, Baltimore, MD, Merck Research
Laboratories, West Point, PA, each study recruitment
site, and the Institutional Review Board of the Thailand
Ministry of Health (MOH), Thailand.
At enrollment, information on sociodemographic
characteristics, sexual risk behavior, reproductive and
contraceptive history, current contraceptive usage sta-
tus, self-reported medical history, and woman’s report
of the sexual behavior of her partner was collected at
each study site by trained interviewers using a stan-
dardized questionnaire.
Sexual behavior variables included age of sexual debut,
lifetime number of sexual partners, number of sexual
partners in the last six months (L6M) and/or new sexual
partners acquired in the last year (L12M), commercial
sex work L6M, condom use with primary partner L6M
or most recent sexual partner if no primary partners are
reported by the participant, and primary partner risk be-
haviors. Reproductive information included total number
of pregnancy and live births. Contraceptive use was
broadly classified as 1) combined low-dose oral contra-
ceptives (COC); 2) depomedroxyprogesterone acetate
(DMPA); 3) other injectable methods; and 4) non-
hormonal contraceptive use and non-use (NHC). Current
use and duration of use prior to enrollment for each cat-
egory of hormonal contraception were assessed.
Questionnaire and physical exam data from the original
HC-HIV study were extracted and linked to the partici-
pants. Laboratory-confirmed STI status was collected
from the two year period prior to study enrollment andincluded gonorrhea (GC), chlamydia (CT), syphilis (SYP),
and Bacterial Vaginosis (BV).
Physical examination and specimen collection
At enrollment, each participant underwent a pelvic exam-
ination. Exfoliated cervical cells were collected using a
cytobrush and placed in PreservCyt™ for Thinprep™
liquid-based cytology. CT and GC detection from an ecto-
cervical mucus specimen was performed using the Roche
Amplicor assay per manufacturer’s instructions (Roche
Molecular Systems, Alameda, CA). An endo/ecto cervical
swab specimen was collected by study clinicians for HPV
DNA genotyping using a Dacron swab stored in Specimen
Transport Medium (STM) (Digene) at −20○C until testing.
Bacterial Vaginosis was diagnosed by the Ames test.
All Pap smear and biopsy specimens were read by
trained cytopathologists (Covance, Indianapolis, IN). Cyto-
logical smears were classified according to the Bethesda
system [7]. Participants with an abnormal Pap smear diag-
nosis of atypical squamous cell of undetermined signifi-
cance (ASC-US) or more severe (≥ ASC-US) were referred
for colposcopic examination with biopsy and treatment as
indicated. Colposcopy directed biopsies were reported as a
diagnosis of Normal, Cervical Intraepithelial Neoplasia 1
(CIN 1), Cervical Intraepithelial Neoplasia II (CIN 2), and
Cervical Intraepithelial Neoplasia 3 (CIN 3). Biopsies were
read and interpreted by one study pathologist.
HPV DNA testing
All HPV DNA testing was performed on cervical cell sam-
ples stored in STM (Digene) at Johns Hopkins University,
Baltimore, MD. DNA was extracted using the QIAamp
DNA Blood Kit (Qiagen, Courtaboeuf, France) according
to manufacturer’s instructions with modification. After ex-
traction, DNA was tested using the Roche HPV Linear
array© PCR assay (Roche Diagnostics, Indianapolis, IN).
The HPV Linear Array© is based on the PGMY09/11 pri-
mer system that allows for high efficiency amplification of
37 types of HPV [8,9]. The quality and validity of the ex-
tracted DNA specimen was assessed by inclusion of β-
globin gene-specific primers in the PCR reaction; only
specimens with detectable β-globin were used in this
analysis.
HPV types considered to be high risk (HR-HPV) for
this analysis included 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68, 73, 82 [3,10]. Low risk (LR) HPV types in-
cluded all other HPV types detected by the HPV Linear
Array©. Multiple infections that include a HR-HPV type
were classified as high risk regardless of the presence of
other low risk co-infections.
Statistical analysis
The prevalence of HPV any, high-risk HPV (HR-HPV),
low-risk HPV (LR-HPV), and type-specific infection was
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those with a diagnosis of CIN 2/3 at enrollment.
Contingency tables were created to assess the distribu-
tion of demographic, sexual, clinical, and reproductive fac-
tors by detection of HPV DNA. Due to the high
prevalence of HPV in the study sample, univariate preva-
lence ratios (PR) were estimated using a generalized linear
model with a Poisson function and robust variance to as-
sess the strength of the association between a given risk
factor and detection of any HPV or any HR-HPV type [11].
Covariates with a p-value of <0.1 in univariate ana-
lyses were considered for inclusion in the multivariate
regression model. Following this initial selection, vari-
ables were removed from the model in a stepwise fash-
ion and a likelihood ratio test was performed after
removal of each variable to confirm the variables contri-
bution to the model’s goodness-of-fit and to identify the
most parsimonious model. Age and study site were
retained in the multivariate model. After identifying
the final multivariate model using an outcome of any
HPV infection, separate multivariate models were then
generated that assessed the relationship of the identified
demographic, behavioral and clinical factors on other
outcomes such as (1) any HR-HPV infections; (2) HPV
52 infections; and (3) HPV 52 infections without
HPV16 infections. The statistical significance of trends
for PRs was assessed by including a categorical variable
as a continuous variable in the regression model.
The final model for any HPV infection was stratified by
cytological diagnosis at baseline (Normal vs. Abnormal
[including inflammation, ASCUS, LSIL, and HSIL]). A
p-value of <0.05 was considered statistically significant
in the final multivariate model for the association of a
given variable and detection of HPV DNA. All analyses
were conducted using STATA 11.0 (STATACORP,
College Station, TX).
Results
At enrollment, 6 (0.4%) of the 1256 samples were β-globin
negative leaving a total of 1250 samples for analysis. Over-
all, 307 (24.6%) and 175 (14.0%) of women were positive
for any HPV or any HR-HPV type (57% of HPV DNA
positive women), respectively (Table 1). There were 94
(7.6%) of women with multiple HPV infections (30.9% of
HPV-positive women). The three most common types
found in either a single or multiple infection were the low
risk types 72 (4.1%) and 62 (2.9%) as well as the high-risk
type 52 (3.6%). A total of 11 women had a histological
diagnosis of CIN2/3 at enrollment. Among women diag-
nosed with CIN 2/3, the prevalence of any HPV type and
any HR-HPV type was 90.9% for both categories. The two
most prevalent HPV types detected among women with
CIN 2/3 was HPV 52 (63.6%) and HPV 16 (27.3%).Correlates of prevalent HPV infection
At enrollment, 33 (2.6%) women had missing parity data,
1 (0.1%) woman had a missing STI diagnosis data, and 5
women who reported use of other injectable contracep-
tives were excluded from the analysis leaving 1,201
women to examine the association of risk factors for
prevalent HPV infection.
The prevalence of an HPV infection was significantly
lower among women reporting one or more live births
as compared to those with none (24.5% vs. 22.1%; p <
0.001) (Table 2). The prevalence of any HPV was signifi-
cantly higher among women reporting greater than
6 years of COC use as compared to never users (31.5%
vs. 21.1%; p < 0.001). The prevalence of any HPV was
significantly higher among current smokers as compared
to non-smokers (56.4% vs. 22.5%; p < 0.001). Lastly, a
higher HPV prevalence was observed among women
with risker sexual behavior such as younger age of sexual
debut, increased number of recent and lifetime partners,
and women reporting commercial sex work. Similar as-
sociations with demographic and reproductive factors
were observed for HR-HPV infections.
A higher prevalence of any HPV was observed in
women with a cytological diagnosis of inflammation
(43.8%), AS-CUS (36.5%), LSIL (80.9%), or HSIL (71.4%)
as compared to normal (20.3%) (p < 0.001) (Table 3). A
higher prevalence of HPV was observed among women
with a prior diagnosis of genital ulcers (36.2% vs. 22.0%;
p < 0.001) and genital warts (42.2% vs. 23.5%; p = 0.01).
No women had genital warts or ulcers upon physical
examination at study enrollment. Women with a prior
and current diagnosis of gonnorhea, chlamyida, and bac-
terial vaginosis had a significantly higher prevalence of
any HPV infection. Similar associations were observed
with HR-HPV infections.
In multivariate analysis (Table 4), prevalent infection
with any HPV and any HR-HPV was associated with pri-
mary partner sexual behavior, >6 years cumulative use of
COCs, an increased number of lifetime partners, prior de-
tection of Chlamydia, and current diagnosis of bacterial
vaginosis. The magnitude of the prevalence ratios were
similar when analyses were restricted to individuals with
HPV 52 infections with or without concurrent HPV 16
infections but the associations did not reach statistical
significance due to reduced sample size. There was lit-
tle to no difference in prevalence ratios among women
with and without cytological abnormalities (Additional
file 1: Table S1).
Discussion
We identified a high prevalence of any HPV and any
HR-HPV infection in a large population-based study of
women recruited from seven family planning clinics
across different geographic regions of Thailand. HPV 52
Table 1 Prevalence of cervical HPV infections overall and among those with prevalent CIN 2/3 cases
Type Prevalence (N = 1250) Prevalence among those with prevalent CIN 2/3 (n = 11)
n(%) n (%) (95% CI)
HPV DNA negative 943 1 (9.1) (0.2, 41.3)
Any HPV positive 307 (24.6) 10 (90.9) (58.7, 99.8)
Any HR-HPV positive 175 (14) 10 (90.9) (58.7, 99.8)
Any LR-HPV positive 170 (13.6) 2 (18.2) (2.3, 51.8)
High-Risk Infections:
HPV 16 26 (2.1) 3 (27.3)
HPV 18 9 (0.7) 2 (18.2) (2.3, 51.8)
HPV 31 7 (0.6) 0 ———
HPV 33 7 (0.6) 1 (9.1) (0.7, 20.2)
HPV 35 3 (0.2) 0 ———
HPV 39 20 (1.6) 1 (9.1) (0.2, 41.3)
HPV 45 3 (0.2) 1 (9.1) (0.2, 41.3)
HPV 51 23 (1.8) 0 ———
HPV 52 45 (3.6) 7 (63.6) (30.8, 89.1)
HPV 56 6 (0.5) 0 ———
HPV 58 11 (0.9) 0 ———
HPV 59 12 (0.9) 0 ———
HPV 68 21 (1.7) 1 (9.1) (0.2, 41.3)
HPV 73 6 (0.5) 0 ———
HPV 82 6 (0.5) 0 ———
Low-Risk Infections:
HPV 6 1 (0.1) 0 ———
HPV 11 1 (0.1) 0 ———
HPV 26 0 0 ———
HPV is39 2 (0.2) 0 ———
HPV 40 4 (0.3) 0 ———
HPV 42 6 (0.5) 0 ———
HPV 53 27 (2.2) 0 ———
HPV 54 13 (1.0) 0 ———
HPV 55 8 (0.6) 0 ———
HPV 61 3 (0.2) 0 ———
HPV 62 36 (2.9) 0 ———
HPV 64 3 (0.2) 0 ———
HPV 66 7 (0.6) 0 ———
HPV 67 2 (0.2) 1 (9.1) (0.2, 41.3)
HPV 69 1 (0.1) 0 ———
HPV 70 27 (2.2) 0 ———
HPV 71 22 (1.8) 0 ———
HPV 72 51 (4.1) 1 (9.1) (0.2, 41.3)
HPV 81 9 (0.7) 0 ———
HPV 83 1 (0.1) 1 (9.1) (0.2, 41.3)
HPV 84 14 (1.1) 0 ———
HPV 89 4 (0.3) 0 ———
Marks et al. BMC Infectious Diseases  (2015) 15:159 Page 4 of 11
Table 1 Prevalence of cervical HPV infections overall and among those with prevalent CIN 2/3 cases (Continued)
HPV 16 (w/o HPV 52) 22 (1.8) 1 (9.1) (0.2, 41.3)
HPV 52 (w/o HPV 16) 41 (3.5) 5 (45.5) (16.7, 76.6)
Other HR-HPV types (w/o HPV 16/52) 105 (10.6) 2 (18.2) (2.3, 51.8)
LR-HPV (w/o HR-HPV) 115 (8.4) 2 (18.2) (2.3, 51.8)
Number of unique HPV types detected:
1 212 (16.9) 4 (36.4) (10.9, 69.2)
2 62 (4.9) 3 (27.3) (6.0, 60.9)
3 22 (1.8) 3 (27.3) (6.0, 60.9)
4 7 (0.6) 0 ———
5 4 (0.3) 0 ———
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prevalence of HPV was found to be associated with
long-term use of combined oral contraceptives and prior
and current diagnosis of sexually transmitted diseases,
which appeared to remain significant after adjustment
for sexual behavior. This study represents one of the lar-
gest and most comprehensive evaluations of HPV preva-
lence and correlates of infection in Thailand, a country
where cervical cancer is one of most common cancers of
women of reproductive age and a significant source of
cancer-related mortality.
HPV 52 was the most common HPV type detected
among women both with and without cervical abnor-
malities with a prevalence of 63% among women diag-
nosed with prevalent CIN2/3 as compared to only 27%
for HPV 16. This elevated prevalence of HPV 52 de-
creased to only 45% after exclusion of women with HPV
16 co-infection. The relatively high prevalence of HPV
52 relative to HPV 16 among those with prevalent CIN
2/3 stands in contrast to a recent hospital-based study of
100 cervical tissue specimens collected from women
with HSIL that reported 44.2% and 11.8% attributed to
HPV 16 and HPV 52, respectively [12]. Part of this dif-
ference could be explained by the fact that our study
used cervical swab to detect HPV as compared to biop-
sied cervical tissue. This may have led to detection of
HPV 52 infections that are truly not associated with
CIN 2/3. However, prior population-based studies con-
ducted in Thailand that measured HPV in cervical and
vaginal samples identified HPV 52 as the dominant type
among women with a diagnosis of CIN 2/3 [5,13]. Other
population-based studies assessing HPV prevalence in
low- and middle- income countries show a high level of
variability in the dominance of specific HPV types, par-
ticularly among cytologically normal women, as com-
pared to high-income countries in Europe and the US
where HPV16 is the most common type detected
[14,15]. A meta-analysis utilizing HPV genotype data
from 115,789 HPV positive women from different geo-
graphic regions with normal cytology, low and highgrade pre-cancer, and invasive cancer observed a higher
prevalence and potential greater contribution of HPV52
among women with normal cytology and women with
low and high grade neoplasia as compared to other non-
HPV16 types, particularly in East Asian populations
[16]. However, the relative contribution of HPV52 to
CIN3 and invasive cancer was less robust than other
oncogenic HPV types. These results suggest that, in East
Asian populations, HPV52 may be playing a role in early
stage neoplastic transformation but its role in the pro-
gression to CIN3 and invasive cancer could be poten-
tially less important than other oncogenic HPV types.
This observation provides impetus for future work ex-
ploring the epidemiology and impact of other, non-HPV
16 oncogenic HPV types on cervical disease in middle
and low income settings.
Long-term use of combined oral contraceptives is as-
sociated with an increased risk of cervical cancer diagno-
sis [17]. In Thailand, data from the IARC has estimated
that combined oral contraceptive use is attributed to
23.1% of all cervical cancer cases [18]. Current and long-
term combined oral contraceptive use has also been
shown to increase risk of prevalent HPV infection
among women <30 years of age [19-21]. However, longi-
tudinal studies conducted to assess the association of
COC use with HPV acquisition, persistence, and pro-
gression to pre-cancerous lesions have been inconsistent
[22-29]. A detailed cross-sectional study conducted in
this population confirmed a higher prevalence of any
HPV and any HR-HPV infection among long-term COC
users [21]. This finding agrees with prior longitudinal
analyses which revealed an increased risk of HPV per-
sistence as compared to an increased risk of HPV acqui-
sition among current COC users [22]. Similar analyses
conducted among DMPA users in this study population
did not show any association with HPV prevalence, inci-
dence or persistence in this population, lending to the
specificity of the association. A variety of mechanisms
have been proposed to help explain the potential role of
sex steroid hormones on the natural history of HPV
Table 2 Univariate association of demographic information and reproductive history with prevalent infection of any











(24.1%) (95% CI) (13.6%) (95% CI)
Age category, years
<26 224 26.3% 1.0 18.3% 1.0
26-30 422 22.8% 0.86 (0.65, 1.14) 12.6% 0.69 (0.47, 0.99)
31-33 279 25.1% 0.95 (0.71, 1.28) 11.8% 0.65 (0.42, 0.99)
34-38 276 23.2% 0.89 (0.65, 1.19) 13.0% 0.71 (0.47, 1.08)
Study Site in Thailand
North 429 20.5% 1.0 10.5% 1.0
North-East 274 21.2% 1.03 (0.77, 1.38) 11.7% 1.11 (0.73, 1.71)
South 311 27.9% 1.36 (1.05, 1.77) 16.4% 1.56 (1.08, 2.27)
Central 187 29.9% 1.46 (1.09, 1.95) 18.7% 1.78 (1.19, 2.68)
Years of education
>12 149 28.9% 1.0 14.8% 1.0
10-12 235 20.4% 0.71 (0.49, 1.01) 10.2% 0.69 (0.40, 1.19)
7-9 277 25.9% 0.90 (0.65, 1.24) 15.5% 1.05 (0.65, 1.69)
≤6 540 23.3% 0.81 (0.60, 1.09) 13.7% 0.93 (0.59, 1.44)
# of pregnancies:
0-1 444 23.2% 1.0 14.4% 1.0
2 500 23.2% 1.00 (0.79, 1.26) 12.4% 0.86 (0.62, 1.19)
≥3 257 27.2% 1.17 (0.90, 1.53) 14.4% 0.99 (0.69, 1.45)
# of livebirths
0 27 55.6% 1.0 22.2% 1.0
1 604 24.5% 0.44 (0.31, 0.64) 15.7% 0.71 (0.34, 1.47)
>1 570 22.1% 0.39 (0.27, 0.58) 10.9% 0.49 (0.23, 1.03)
Contraceptive use at enrollment*:
NHC 448 24.8% 1.0 12.5% 1.0
DMPA 347 19.9% 0.80 (0.62, 1.05) 11.8% 0.95 (0.65, 1.38)
COC 406 26.9% 1.08 (0.86, 1.36) 16.3% 1.30 (0.94, 1.81)
Cumulative use of COCs:
Never 194 21.1% 1.0 12.4% 1.0
<4 years 603 22.6% 1.07 (0.78, 1.45) 11.8% 0.95 (0.62, 1.47)
4-6 years 310 23.6% 1.11 (0.79, 1.56) 13.6% 1.09 (0.69, 1.75)
>6 years 94 31.5% 1.96 (1.37, 2.82) 27.7% 2.24 (1.36, 3.68)
Cumulative use of DMPA:
Never 272 27.6% 1.0 15.1% 1.0
<4 years 558 25.3% 0.92 (0.72, 1.16) 13.9% 0.93 (0.65, 1.32)
4-6 years 315 18.7% 0.68 (0.50, 0.92) 11.8% 0.78 (0.52, 1.18)
>6 years 56 25.0% 0.91 (0.55, 1.48) 12.5% 0.83 (0.39, 1.75)
Current Smoker:
No 1146 22.5% 1.0 12.5% 1.0
Yes 55 56.4% 2.50 (1.94, 3.23) 36.4% 2.91 (1.99, 4.27)
Age of sexual debut, years:
>20 459 20.3% 1.0 10.2% 1.0
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Table 2 Univariate association of demographic information and reproductive history with prevalent infection of any
HPV and any HR-HPV type (Continued)
17-19 550 23.6% 1.17 (0.92, 1.48) 13.6% 1.33 (0.94, 1.88)
<17 192 34.4% 1.69 (1.29, 2.22) 21.4% 2.09 (1.42, 3.06)
Lifetime # of sex partners:
1 852 17.4% 1.0 9.7% 1.0
2 179 31.8% 1.83 (1.41, 2.38) 13.9% 1.43 (0.94, 2.18)
3 61 32.8% 1.89 (1.28, 2.78) 18.0% 1.85 (1.04, 3.28)
≥4 109 58.7% 3.38 (2.73, 4.19) 40.4% 4.14 (3.05, 5.63)
# Partners L6M**:
0 29 10.3% 1.0 3.5% 1.0
1 1,133 22.8% 2.20 (0.75, 6.46) 12.4% 3.58 (0.52, 24.8)
>1 39 71.8% 6.94 (2.33, 20.6) 56.4% 16.4 (2.34, 114.6)
New partner L12M:***
No 1128 22.7% 1.0 12.5% 1.0
Yes 44 68.2% 3.00 (2.39, 3.78) 47.7% 3.82 (2.70, 5.39)
Commercial Sex Work L6M :
No 1167 22.7% 1.0 12.3% 1.0
Yes 34 70.6% 3.11 (2.44, 3.96) 55.9% 4.53 (3.24, 6.34)
Condom use L6M:
No 977 20.9% 1.0 11.6% 1.0
Yes 224 37.5% 1.79 (1.45, 2.20) 22.3% 1.93 (1.43, 2.60)
Primary partner L6M:
Yes 1164 23.9% 1.0 13.5% 1.0
No 8 87.5% 3.65 (2.76, 4.84) 62.5% 4.63 (2.66, 8.08)
Primary partner had sex with other† L6M:****
No 902 20.6% 1.0 11.2% 1.0
Yes 76 48.7% 2.36 (1.81, 3.07) 30.3% 2.70 (1.83, 3.98)
Don’t Know 186 30.1% 1.46 (1.13, 1.88) 17.7% 1.58 (1.11, 2.27)
*NHC = Non-Hormonal Contraception; DMPA = DepotMedroxyprogesterone Acetate; COC = Combined oral contraception **L6M = Last six months prior to
enrollment; L12M = Last twelve months prior to enrollment ***Among those who report > =1 sexual partner L6M ****Among those who report a primary partner
L6M †Includes commercial and non-commercial sexual partners.
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enhanced acquisition of HPV; (b) modulation of host
immune response by sex steroid hormones facilitating
HPV persistence and development of cervical pre-cancer;
(c) facilitating progression of an already established pre-
cancerous lesion to invasive disease [30]. Additional stud-
ies in populations from other geographic regions are
needed to clarify the epidemiologic association between
COC use and HPV to strengthen the mechanistic
hypothesis.
We observed higher prevalence of HPV infection among
women diagnosed with either a current or prior history of
bacterial vaginosis or Chlamydia Trachomatis. These asso-
ciations remain significant even after adjustment for sex-
ual behavior. Bacterial vaginosis is characterized as an
alteration of the vaginal microflora that can result in in-
flammation and significant morbidity. Bacterial vaginosishas been suggested to increase the risk of HPV acquisi-
tion, presumably through disruption of non-specific phys-
ical immune barriers by alteration of vaginal pH [31]. A
recent prospective study of over 9000 women from Costa
Rica has shown that increases in vaginal pH were posi-
tively associated with HPV infection [32]. Chlamydia Tra-
chomatis is one of the most common sexually transmitted
infections worldwide, second only to HPV, and is asso-
ciated with complications such as pelvic inflammatory
disease, cervicitis, ectopic pregnancy and infertility.
Chlamydia infection is associated with increasing the
risk of HPV persistence, presumably through disruption
of the mucosal immune response [33]. Although we
cannot determine the temporal relationship of these
genital tract infections on detection of HPV DNA in
this study, our findings agree with other large cohort
studies in where there was a similar detailed collection
Table 3 Univariate association of cytological diagnosis, clinical and STI history with prevalent infection with any HPV
and any HR-HPV type
Variable Sample
N = 1201
HPV + ve N = 289 HR-HPV + ve N = 163
(24.1%) uPR (95% CI) (13.6%) uPR (95% CI)
Pap smear diagnosis:
Normal 1077 20.3% 1.0 10.3% 1.0
Inflammation 16 43.8% 2.15 (1.22, 3.79) 25.0% 2.43 (1.02, 5.77)
AS-CUS 52 36.5% 1.79 (1.23, 2.62) 28.9% 2.79 (1.76, 4.44)
LSIL 42 80.9% 3.98 (3.30, 4.81) 57.1% 5.54 (4.04, 7.60)
HSIL 14 71.4% 3.51 (2.47, 4.99) 64.3% 6.24 (4.06, 9.57)
Genital ulcer ever:
No 1027 22.0% 1.0 12.5% 1.0
Yes 174 36.2% 1.64 (1.31, 2.07) 20.1% 1.61 (1.15, 2.26)
Genital warts ever:
No 1168 23.5% 1.0 13.4% 1.0
Yes 33 42.2% 1.80 (1.19, 2.72) 18.2% 1.35 (0.65, 2.83)
PID ever:
No 1151 23.6% 1.0 13.5% 1.0
Yes 50 34.0% 1.44 (0.96, 2.15) 16.0% 1.19 (0.62, 2.28)
Ever Gonnorhea:
No 1162 23.2% 1.0 12.6% 1.0
Yes 39 48.7% 2.10 (1.49, 2.94) 43.6% 3.47 (2.35, 5.11)
Ever Chlamydia:
No 1044 21.7% 1.0 11.3% 1.0
Yes 157 40.1% 1.85 (1.48, 2.32) 28.7% 2.54 (1.88, 3.42)
Ever Syphilis:
No 1183 24.0% 1.0 13.5% 1.0
Yes 18 27.8% 1.16 (0.55, 2.45) 16.7% 1.23 (0.43, 3.49)
Current gonnorhea:
No 1199 24.0% 1.0 13.5% 1.0
Yes 2 50.0% 2.08 (0.52, 8.36) 50 .0% 3.70 (0.92, 14.9)
Current Chlamydia:
No 1186 23.6% 1.0 13.1% 1.0
Yes 15 60.0% 2.54 (1.66, 3.89) 53.3% 4.08 (2.49, 6.7)
Ever Bacterial Vaginosis.:
No 980 21.5% 1.0 11.9% 1.0
Yes 221 35.3% 1.64 (1.32, 2.03) 20.8% 1.74 (1.28, 2.37)
Current Bacterial Vaginosos.:
No 1142 22.8% 1.0 12.7% 1.0
Yes 59 49.2% 2.16 (1.63, 2.86) 30.5% 2.40 (1.59, 3.64)
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were conducted.
This study has several strengths. First, the use of
highly sensitive and specific laboratory assays for HPV
detection and genotyping allows for a higher degree of
internal validity and better assessment of the outcomemeasures. The use of histological and cytological methods
for diagnosis of CIN helps minimize potential over-
reporting of disease endpoints. Second, given the study
cohort was derived from a study assessing the effects of
hormonal contraceptive use on HIV acquisition, de-
tailed information regarding reproductive factors such
Table 4 Multivariate association of factors with prevalent infection of any HPV and any HR-HPV
Variable Adjusted PR (95% CI)**
Any HPV Any HR-HPV HPV 52 HPV 52 (w/o HPV 16)
Age at enrollment:
<26 1.0 1.0 1.0 1.0
26-30 0.89 (0.68, 1.16) 0.73 (0.49, 1.06) 0.99 (0.46, 2.11) 0.99 (0.46, 2.11)
31-33 1.02 (0.77, 1.37) 0.72 (0.47, 1.09) 0.51 (0.19, 1.35) 0.51 (0.19, 1.35)
34-38 0.95 (0.70, 1.29) 0.73 (0.48, 1.13) 0.35 (0.12, 1.03) 0.35 (0.12, 1.03)
Cumulative use of COCs*:
Never 1.0 1.0 1.0 1.0
<4 years 1.17 (0.87, 1.58) 1.06 (0.71, 1.59) 0.50 (0.22, 1.10) 0.49 (0.22, 1.10)
4-6 years 1.21 (0.87, 1.69) 1.24 (0.79, 1.94) 1.03 (0.46, 2.32) 1.03 (0.46, 2.33)
>6 years 2.03 (1.39, 2.96) 2.47 (1.45, 4.19) 1.16 (0.39, 3.45) 1.16 (0.39, 3.45)
# lifetime partners
1 1.0 1.0 1.0 1.0
2 1.66 (1.29, 2.14) 1.21 (0.80, 1.82) 1.05 (0.43, 2.57) 1.05 (0.43, 2.57)
3 1.54 (1.04, 2.26) 1.25 (0.69, 2.28) 1.99 (0.67, 5.89) 1.99 (0.67, 5.89)
≥4 2.02 (1.54, 2.66) 1.98 (1.35, 2.91) 1.97 (0.87, 4.45) 1.97 (0.87, 4.45)
Primary partner had sex w/others:
No 1.0 1.0 1.0 1.0
Yes 1.42 (1.05, 1.91) 1.35 (0.89, 2.04) 2.32 (0.98, 5.50) 2.32 (0.98, 5.50)
Don’t Know 1.29 (1.02, 1.64) 1.34 (0.94, 1.91) 1.48 (0.69, 3.15) 1.48 (0.69, 3.15)
Chlamydia infection ever:
No 1.0 1.0 1.0 1.0
Yes 1.32 (1.04, 1.66) 1.74 (1.27, 2.38) 1.25 (0.54, 2.92) 1.25 (0.54, 2.92)
Bacterial Vaginosis at enrollment:
No 1.0 1.0 1.0 1.0
Yes 2.11 (1.54, 2.91) 1.98 (1.28, 3.06) 2.28 (0.96, 5.39) 2.28 (0.96, 5.39)
*COC = Combined oral contraception.
**All variables mutually adjusted for in final model.
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ior and other risk factors were collected which allowed
for a thorough investigation of these exposures on the
risk of HPV prevalence.
Limitations of the study include the cross-sectional de-
sign which limits the ability to ascribe a temporal rela-
tionship between the factors examined and HPV
outcomes. Prospective studies are therefore needed to
address the association of these factors on endpoints of
HPV such as acquisition and persistence. Additionally, it
is important to note that sexual behavior information, in
particular male partner behavior, was based on partici-
pant self-report and therefore may underestimate the
prevalence of certain risky sexual behaviors that may in-
crease the association with HPV infection. Finally, the
generalizability of the study’s findings may be limited.
The reported prevalence of any HPV and any HR-HPV
in this study is about 4-times higher than previouslyreported population-based prevalence survey’s in
Thailand using similar HPV detection and genotyping
assay’s with similar levels of sensitivity [5,13]. The
current study sampled women between the ages of 20–
37 years from varied geographic settings in Thailand
who were family-planning clinic attendees. These
women may, therefore be at elevated risk of HPV expos-
ure and infection relative to the general population.
However, the similarity of HPV type distribution among
both diseased and non-diseased women, particularly
with respect to HPV 52, in this population as compared
to previous studies lends strength to the relevance and
generalizability of these findings in the broader context
of the epidemiology of HPV in Thailand.
The current study demonstrates a uniquely high
prevalence of HR-HPV types such as HPV 52 among
women with cervical pre-cancer in Thailand. These data
provide descriptive information for development and
Marks et al. BMC Infectious Diseases  (2015) 15:159 Page 10 of 11implementation of prophylactic interventions, including
vaccine formulations that target a broader spectrum of
oncogenic HPV types.
Conclusions
The prevalence of any HPV and HR-HPV in this sample
of high risk women attending family planning clinics
throughout Thailand is 24.6% and 14.0% with HPV type
52 being the most common HPV type among women
with both normal and abnormal cervical cytology and
women with biopsy confirmed CIN 2/3. The prevalence
estimates of any HPV type and HPV 52 in this popula-
tion could be used update regional and country-specific
estimates on the burden of HPV among healthy women
and women with low and high grade cervical disease.
Long-term use of hormonal contraception, laboratory
confirmed Chlamydia infection, and bacterial vaginosis
was associated with an elevated prevalence of any HPV
and any HR-HPV. The identification of these specific
and modifiable risk factors could help guide secondary
prevention measures for cervical cancer such as targeted
screening programs. Overall these study results call for
additional, longitudinal studies on the natural history of
HPV in Thailand where cervical cancer is one of the
most important contributors of cancer-related morbidity
and mortality among women of reproductive age.
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